The Vero cell-derived, inactivated, SA14-14-2 strain-based vaccine (Ixiaro) for prevention of Japanese encephalitis

Expert Review of Vaccines

Volumn 14, Issue 9, 2015, Pages 1167-1179

  Erra, Elina O ^a,b   Kantele, Anu ^b,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

immunogenicity; Ixiaro; Japanese encephalitis; Japanese encephalitis vaccine; JE VC; safety; traveler

Indexed keywords

JAPANESE ENCEPHALITIS VACCINE; INACTIVATED VACCINE;

ABNORMAL BEHAVIOR; ARTICLE; CLINICAL FEATURE; CONSCIOUSNESS DISORDER; CONVULSION; CROSS PROTECTION; DISEASE TRANSMISSION; DRUG APPROVAL; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG USE; ECTOPIC PREGNANCY; FEVER; FLACCID PARALYSIS; GENOTYPE; GROUPS BY AGE; HEADACHE; HUMAN; IMMUNITY; IMMUNOGENICITY; JAPANESE ENCEPHALITIS; JAPANESE ENCEPHALITIS VIRUS; MOTOR DYSFUNCTION; MOUSE MODEL; MUSCLE RIGIDITY; NONHUMAN; PRIORITY JOURNAL; SPONTANEOUS ABORTION; SYNDACTYLY; TRAVEL; TREMOR; VACCINATION; VERO CELL LINE; VIRUS GENE; VIRUS STRAIN; ANIMAL; CHLOROCEBUS AETHIOPS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENCEPHALITIS, JAPANESE; HEALTH; IMMUNOLOGY; ISOLATION AND PURIFICATION; PATHOLOGY; PHARMACEUTICS; PROCEDURES; VIRUS CULTURE;

ANIMALS; CERCOPITHECUS AETHIOPS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENCEPHALITIS, JAPANESE; GLOBAL HEALTH; HUMANS; JAPANESE ENCEPHALITIS VACCINES; TECHNOLOGY, PHARMACEUTICAL; TRAVEL; VACCINES, INACTIVATED; VERO CELLS; VIRUS CULTIVATION;

EID: 84939436228     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2015.1061939     Document Type: Article

References (85)

1. Japanese encephalitis: status of surveillance and immunization in Asia and the Western Pacific, 2012. Wkly Epidemiol Rec 2013; 88(34):357-64
2. Campbell GL, Hills SL, Fischer M, et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ 2011;89(10):766-74
3. Simmonds P, Becher P, Collett MS, et al. Family - flaviviridae. In: King AM, Adams MJ, Carstens EB, Lefkowitz EJ, editors. Virus taxonomy. Ninth report of the international committee on taxonomy of viruses. Elsevier; London, UK: 2011. p. 1003-20
4. Solomon T, Ni H, Beasley DW, et al. Origin and evolution of Japanese encephalitis virus in southeast Asia. J Virol 2003;77(5):3091-8
5. Tsarev SA, Sanders ML, Vaughn DW, et al. Phylogenetic analysis suggests only one serotype of Japanese encephalitis virus. Vaccine 2000;18(Suppl 2):36-43
6. Endy TP, Nisalak A. Japanese encephalitis virus: ecology and epidemiology. Curr Top Microbiol Immunol 2002;267:11-48
7. van den Hurk AF, Ritchie SA, Mackenzie JS. Ecology and geographical expansion of Japanese encephalitis virus. Annu Rev Entomol 2009;54:17-35
8. Pyke AT, Williams DT, Nisbet DJ, et al. The appearance of a second genotype of Japanese encephalitis virus in the Australasian region. Am J Trop Med Hyg 2001;65(6):747-53
9. Nga PT, del Carmen Parquet M, Cuong VD, et al. Shift in Japanese encephalitis virus (JEV) genotype circulating in northern Vietnam: implications for frequent introductions of JEV from southeast Asia to east Asia. J Gen Virol 2004;85(Pt 6):1625-31
10. Nitatpattana N, Dubot-Peres A, Gouilh MA, et al. Change in Japanese encephalitis virus distribution, Thailand. Emerg Infect Dis 2008;14(11):1762-5
11. Yun SM, Cho JE, Ju YR, et al. Molecular epidemiology of Japanese encephalitis virus circulating in South Korea, 1983-2005. Virol J 2010;7:127
12. Schuh AJ, Ward MJ, Leigh Brown AJ, et al. Dynamics of the emergence and establishment of a newly dominant genotype of Japanese encephalitis virus throughout Asia. J Virol 2014;88(8):4522-32
13. Su CL, Yang CF, Teng HJ, et al. Molecular epidemiology of Japanese encephalitis virus in mosquitoes in Taiwan during 2005-2012. PLoS Negl Trop Dis 2014;8(10):e3122
14. Li MH, Fu SH, Chen WX, et al. Genotype v Japanese encephalitis virus is emerging. PLoS Negl Trop Dis 2011;5(7):e1231
15. Takhampunya R, Kim HC, Tippayachai B, et al. Emergence of Japanese encephalitis virus genotype V in the Republic of Korea. Virol J 2011;8:449
16. Kim H, Cha GW, Jeong YE, et al. Detection of Japanese encephalitis virus genotype V in Culex orientalis and Culex pipiens (Diptera: Culicidae) in Korea. PLoS One 2015;10(2):e0116547
17. Griffiths MJ, Turtle L, Solomon T. Japanese encephalitis virus infection. Handb Clin Neurol 2014;123:561-76
18. Solomon T, Vaughn DW. Pathogenesis and clinical features of Japanese encephalitis and West Nile virus infections. Curr Top Microbiol Immunol 2002;267:171-94
19. Hills S, Dabbagh A, Jacobson J, et al. Evidence and rationale for the World Health Organization recommended standards for Japanese encephalitis surveillance. BMC Infect Dis 2009;9:214
20. WHO. WHO-recommended standards for surveillance of selected vaccine-preventable diseases, 2003. Available from: http://apps. who.int/iris/bitstream/10665/68334/1/WHO-V-B-03.01-eng.pdf?ua=1 [Last accessed 28 May 2015]
21. Lehtinen VA, Huhtamo E, Siikamaki H, et al. Japanese encephalitis in a Finnish traveler on a two-week holiday in Thailand. J Clin Virol 2008;43(1):93-5
22. Buhl MR, Lindquist L. Japanese encephalitis in travelers: review of cases and seasonal risk. J Travel Med 2009;16(3): 217-19
23. Hatz C, Werlein J, Mutsch M, et al. Japanese encephalitis: defining risk incidence for travelers to endemic countries and vaccine prescribing from the UK and Switzerland. J Travel Med 2009;16(3):200-3
24. Hills SL, Griggs AC, Fischer M. Japanese encephalitis in travelers from non-endemic countries, 1973-2008. Am J Trop Med Hyg 2010;82(5):930-6
25. Halstead SB, Jacobson J, Dubischar-Kastner K. Japanese encephalitis vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th edition. Saunders Elsevier; 2012. p. 312-51
26. Centers for Disease Control and Prevention (CDC). Japanese encephalitis in two children-United States, 2010. MMWR Morb Mortal Wkly Rep 2011;60(9):276-8
27. Werlinrud AM, Christiansen CB, Koch A. Japanese encephalitis in a Danish short-term traveler to Cambodia. J Travel Med 2011; 18(6):411-13
28. Jeurissen A, Strauven T. A case of aseptic meningitis due to Japanese encephalitis virus in a traveller returning from the Philippines. Acta Neurol Belg 2011;111(2):143-5
29. Lee DW, Choe YJ, Kim JH, et al. Epidemiology of Japanese encephalitis in South Korea, 2007-2010. Int J Infect Dis 2012;16(6):e448-52
30. Tappe D, Nemecek A, Zipp F, et al. Two laboratory-confirmed cases of Japanese encephalitis imported to Germany by travelers returning from Southeast Asia. J Clin Virol 2012;54(3):282-5
31. Doti P, Castro P, Martinez MJ, et al. A case of Japanese encephalitis in a 20 year-old Spanish sportsman, February 2013. Euro Surveill 2013;18(35):20573
32. Lagarde S, Lagier JC, Charrel R, et al. Japanese encephalitis in a French traveler to Nepal. J Neurovirol 2014;20(1):99-102
33. Hills SL, Stoltey J, Martinez D, et al. A case series of three US adults with Japanese encephalitis, 2010-2012. J Travel Med 2014;21(5):310-13
34. Langevin S, Libman M, Drebot MA, et al. A case of Japanese encephalitis virus infection acquired during a trip in Thailand. J Travel Med 2012;19(2):127-9
35. Japanese Encephalitis Vaccines: WHO position paper - February 2015. Wkly Epidemiol Rec 2015;90(9):69-87
36. Gavi, the Vaccine Alliance. Supplementary guidelines for Japanese encephalitis applications in 2015. Available from: www.gavi.org/support/nvs/japanese-encephalitis/ [Last accessed 28 May 2015]
37. Centers for Disease Control and Prevention (CDC). Use of Japanese encephalitis vaccine in children: recommendations of the advisory committee on immunization practices 2013. MMWR Morb Mortal Wkly Rep 2013;62(45):898-900
38. Background paper on JE Vaccines-SAGE working group. Available from: www.who. int/immunization/sage/meetings/2014/october/1-JE-Vaccine-Background-Paper.pdf?ua=1 [Last accessed 28 May 2015]
39. Appaiahgari MB, Vrati S. IMOJEV((R)): a Yellow fever virus-based novel Japanese encephalitis vaccine. Expert Rev Vaccines 2010;9(12):1371-84
40. Eckels KH, Yu YX, Dubois DR, et al. Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA14-14-2; adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use. Vaccine 1988;6(6):513-18
41. Srivastava AK, Putnak JR, Lee SH, et al. A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine 2001;19(31):4557-65
42. FDA. Ixiaro. Product Information. Package Insert and Patient Information. Available from: www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142569.pdf [Last accessed 28 May 2015]
43. European Medicines Agency. Ixiaro: EPAR - product information. Annex 1: Summary of Product Characteristics. Available from: www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000963/WC500037287.pdf [Last accessed 28 May 2015]
44. World Health Organization. Public assessment summary report update-Japanese encephalitis vaccine (Human) (Purified inactivated vaccine-adsorbed) JEEV. WHO 2014. Available from: http://www.who.int/immunization-standards/vaccine-quality/pq-266-je-1dose-biologicale-updated-vpsar.pdf?ua=1 [Last accessed 28 May 2015]
45. World Health Organization. Recommendations for inactivated Japanese encephalitis vaccine for human use. In: WHO expert committee on biological standardization, fifty-eight report. WHO Technical Report Series, No. 963, Annex 1 2011. Available from: http://apps.who.int/medicinedocs/documents/s19541en/s19541en.pdf [Last accessed 28 May 2015]
46. Hombach J, Solomon T, Kurane I, et al. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 2005;23(45):5205-11
47. Van Gessel Y, Klade CS, Putnak R, et al. Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO ((R))) induced neutralizing antibody titers. Vaccine 2011;29(35):5925-31
48. Lyons A, Kanesa-thasan N, Kuschner RA, et al. A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis. Vaccine 2007;25(17):3445-53
49. Tauber E, Kollaritsch H, Korinek M, et al. Safety and immunogenicity of a Vero-cellderived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 2007; 370(9602):1847-53
50. Schuller E, Klade CS, Wolfl G, et al. Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study. Vaccine 2009;27(15):2188-93
51. Kaltenbock A, Dubischar-Kastner K, Eder G, et al. Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study. Vaccine 2009;27(33):4483-9
52. FDA. Clinical review of new biologics license application STN# 125280/0 - IXIARO 2009. Available from: www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM144417.pdf [Last accessed 28 May 2015]
53. EMA. Assessment report for Ixiaro. Procedure No. EMEA/H/C/000963 2009. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/000963/WC500037286.pdf [Last accessed 28 May 2015]
54. Woolpert T, Staples JE, Faix DJ, et al. Immunogenicity of one dose of Vero cell culture-derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine. Vaccine 2012;30(20):3090-6
55. Erra EO, Askling HH, Rombo L, et al. A single dose of vero cell-derived Japanese encephalitis (JE) vaccine (Ixiaro) effectively boosts immunity in travelers primed with mouse brain-derived JE vaccines. Clin Infect Dis 2012;55(6):825-34
56. Erra EO, Askling HH, Yoksan S, et al. Cross-protective capacity of Japanese encephalitis (JE) vaccines against circulating heterologous JE virus genotypes. Clin Infect Dis 2013;56(2):267-70
57. Alberer M, Burchard G, Jelinek T, et al. Co-administration of a meningococcal glycoconjugate ACWY vaccine with travel vaccines: a randomized, open-label, multi-center study. Travel Med Infect Dis 2014;12(5):485-93
58. Jelinek T, Burchard GD, Dieckmann S, et al. Short-term immunogenicity and safety of an accelerated pre-exposure prophylaxis regimen with Japanese encephalitis vaccine in combination with a rabies vaccine: a Phase III, multicenter, observer-blind study. J Travel Med 2015. [Epub ahead of print]
59. EMA. Assessment report. Ixiaro. Procedure No.: EMEA/H/C/000963/II/0039/G. 2013. Available from: www.ema.europa.eu/docs/en-GB/document-library/EPAR-Assessment-Report-Variation/human/000963/WC500142252.pdf [Last accessed 28 May 2015]
60. Chokephaibulkit K, Sirivichayakul C, Thisyakorn U, et al. Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial. Pediatr Infect Dis J 2010;29(12):1111-17
61. Singh A, Mitra M, Sampath G, et al. A Japanese encephalitis vaccine from India induces durable and cross-protective immunity against temporally and spatially wide-ranging global field strains. J Infect Dis 2015. [Epub ahead of print]
62. Jelinek T, Cramer J, Burchard G, et al. Accelerated 1-week vaccination regimens for rabies pre-exposure and Japanese encephalitis prophylaxis. Presented at The 14th Conference of the International Society of Travel Medicine. 24-28 May 2015, Québec City, Canada
63. Dubischar-Kastner K, Eder S, Buerger V, et al. Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO, IC51. Vaccine 2010;28(32):5197-202
64. Schuller E, Jilma B, Voicu V, et al. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study. Vaccine 2008;26(34):4382-6
65. Eder S, Dubischar-Kastner K, Firbas C, et al. Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO(R), IC51. Vaccine 2011;29(14):2607-12
66. Centers for Disease Control and Prevention (CDC). Recommendations for use of a booster dose of inactivated vero cell culture-derived Japanese encephalitis vaccine: advisory committee on immunization practices, 2011. MMWR Morb. Mortal Wkly Rep 2011;60(20):661-3
67. Erra EO, Askling HH, Yoksan S, et al. Cross-protection elicited by primary and booster vaccinations against Japanese encephalitis: a two-year follow-up study. Vaccine 2013;32(1):119-23
68. Paulke-Korinek M, Kollaritsch H, Kundi M, et al. Long term immunity 6 years after booster vaccination against Japanese encephalitis. Presented at The 14th Conference of the International Society of Travel Medicine. 24-28 May 2015; Québec City, Canada
69. Kanamitsu M, Hashimoto N, Urasawa S, et al. A field trial with an improved Japanese encephalitis vaccine in a nonendemic area of the disease. Biken J 1970;13(4):313-28
70. Sohn YM, Park MS, Rho HO, et al. Primary and booster immune responses to SA14-14-2 Japanese encephalitis vaccine in Korean infants. Vaccine 1999;17(18): 2259-64
71. Takeshita N, Lim CK, Mizuno Y, et al. Immunogenicity of single-dose Vero cell-derived Japanese encephalitis vaccine in Japanese adults. J Infect Chemother 2014; 20(4):238-42
72. The National Institute for Health and Welfare (THL). Nohynek H, Elonsalo U. Japanese encephalitis. In: Traveller's Health Guide 2015. Available from: www.terveyskirjasto.fi/terveyskirjasto/ktl.mat?p-artikkeli=mat00039 [Last accessed 28 May 2015] [In Finnish]
73. King A, Lefkowitz E, Adams M, et al. Family - Flaviviridae. In: Virus taxonomy. Ninth report of the international committee on taxonomy of viruses. Elsevier; 2011
74. Schuller E, Klade CS, Heinz FX, et al. Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51. Vaccine 2008; 26(48):6151-6
75. Dubischar-Kastner K, Cramer J, Eder S, et al. Immunogenicity and safety of the inactivated Japanese encephalitis vaccine Ixiaro, IC51, in elderly. Presented at The 13th Conference of the International Society of Travel Medicine. 19-23 May 2013, Maastricht, The Netherlands
76. Chen WH, Kozlovsky BF, Effros RB, et al. Vaccination in the elderly: an immunological perspective. Trends Immunol 2009;30(7):351-9
77. Kaltenbock A, Dubischar-Kastner K, Schuller E, et al. Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age. Vaccine 2010;28(3):834-9
78. FDA. Clinical review - Ixiaro. STN 125280/125. (Clinical reviewer: Fink, DL.) 2013. Available from: www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM354012.pdf [Last accessed 28 May 2015]
79. Dubischar-Kastner K, Kadlecek V, Bézay N, et al. 24-Months antibody persistence in children with and without a booster dose of an inactivated Japanese encephalitis vaccine, JE-VC, IC51. Presented at The 5th Northern European Conference on Travel Medicine. 5-8 June 2014, Bergen, Norway
80. Dubischar-Kastner K, Ayad A, Cramer J, et al. Safety and immunogenicity data for inactivated Japanese encephalitis vaccine (JEVC), IC51, in children from je non-endemic countries. Presented at The 5th Northern European Conference on Travel Medicine. 5-8 June 2014, Bergen, Norway
81. Global advisory committee on vaccine safety,12-13 June 2013. Wkly Epidemiol Rec 2013;88(29):301-12
82. Schuller E, Klingler A, Dubischar-Kastner K, et al. Safety profile of the Vero cell-derived Japanese encephalitis virus (JEV) vaccine IXIARO((R)). Vaccine 2011;29(47):8669-76
83. Müller Z, Dubischar-Kastner K, Hennig R, et al. Post-marketing safety profile of the inactivated Japanese encephalitis vaccine Ixiaro - experience three years after launch. Presented at The 13th Conference of the International Society of Travel Medicine. 19-23 May 2013, Maastricht, The Netherlands
84. Rabe IB, Miller ER, Fischer M, et al. Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009-2012. Vaccine 2015;33(5): 708-12
85. Dubischar-Kastner K, Kaltenboeck A, Klingler A, et al. Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine, IXIARO (IC51), in 6 months of follow-up. Vaccine 2010; 28(39):6463-9